Narkodorm

Quick links to important sections

Narkodorm

Method of action: Hypnotic

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Narkodorm

Quick Facts

Property Description
Active ingredient Pentobarbital (often as Pentobarbital sodium)
Form Injection solution, capsule, suppository
Pharmacological class Barbiturate, CNS Depressant
General Purpose Induction of deep sedation and hypnosis (sleep)
Origin Synthetic substance

Narkodorm is a pharmaceutical product containing the active substance Pentobarbital, often formulated as its water-soluble salt, Pentobarbital sodium. This drug is a potent, synthetic chemical categorized as a single-component preparation. While Pentobarbital is used in human medicine, Narkodorm is specifically encountered in the veterinary field, defining its commercial positioning. The active ingredient is typically supplied as a liquid aqueous solution designed for parenteral (injection) administration, ensuring rapid systemic delivery.

The Barbiturate Classification and Central Nervous System Action

Narkodorm is formally classified in pharmacology as a barbiturate, a group of nonselective CNS depressants. The effects of this class are clinically recognized for their ability to promote powerful sedation and rapidly reduce neural excitability. This pharmacological action is achieved by significantly boosting the effects of the primary inhibitory neurotransmitter, GABA (Gamma-aminobutyric acid). Pentobarbital is categorized as a short-acting barbiturate, offering a rapid onset and short duration of action. The core purpose of this potent CNS depression is to provide deep sedation and hypnosis (sleep induction), which is particularly relevant in urgent situations requiring immediate physiological quietude.

Core Chemical Composition and Physical Forms

The active agent, Pentobarbital, is a derivative of barbituric acid. The substance is often prepared using a vehicle incorporating an aqueous solution with stabilizers like propylene glycol or alcohol to ensure stability and suitability for injection. This specific parenteral formulation is a key differentiator. The medicine's composition is characterized by this single, highly active barbituric acid derivative, which provides its rapid and profound depressing effect on the central nervous system.

Regulatory References

  1. Pentobarbital Overdose: MedlinePlus Medical Encyclopedia

What side effects are possible with Narkodorm?

Possible Side Effects and Safety Information

The safety profile of Narkodorm, which contains the barbiturate Pentobarbital, is defined by its powerful Central Nervous System (CNS) depressant action. This action is the source of the most common expected effects and the most serious safety risks documented in official regulatory labeling.


Documented Adverse Reactions

The most frequent adverse effect reported in official documents is Somnolence (excessive sleepiness), which is classified as Common. Uncommon to Rare reactions are grouped by the affected body system:

System-Organ Class Examples of Documented Reactions
Nervous System Agitation, Confusion, Ataxia, Hyperkinesia, Insomnia, Dizziness
Respiratory System Hypoventilation, Apnea, Respiratory Depression, Laryngospasm
Cardiovascular System Hypotension (low blood pressure), Bradycardia (slow heart rate), Syncope
Gastrointestinal Nausea, Vomiting, Constipation

Serious Safety Concerns and Restrictions

Regulatory documents highlight the potential for severe adverse reactions, including Apnea and Severe Respiratory Depression, and Cardiovascular Collapse, particularly with rapid intravenous administration. Serious Dermatologic Reactions, such as Stevens-Johnson syndrome (SJS), are also documented.

Safety statements note the potential for Tolerance and Physical/Psychological Dependence with prolonged use. Abrupt cessation after extended administration may precipitate severe Withdrawal Symptoms.

Use is formally Contraindicated in individuals with Acute Porphyrias or a known Hypersensitivity to barbiturates. Caution is required for Older Adults and patients with Hepatic or Renal Impairment due to increased susceptibility to adverse effects.

Overdose and Emergency Response

A Narkodorm (Pentobarbital) overdose is officially documented as resulting from profound, dose-dependent central nervous system (CNS) depression. Overdose presentations include severe signs such as stupor, coma, slurred speech, confusion, uncoordinated movement, dizziness, and hypotonia. Staggering gait (ataxia) is a manifestation commonly noted in children.

The condition poses a life-threatening risk due to the rapid progression to respiratory depression and subsequent apnea. This failure often leads to severe hypotension, cardiovascular collapse, and may result in cardiac arrest and death. The risk of severity is officially noted to be increased in aged or ill persons.

Due to the critical nature of these documented manifestations, regulatory authorities mandate that immediate medical help must be sought, and a Poison Control Center must be contacted immediately upon any suspicion of overdose.

Management is strictly symptomatic and supportive, as no specific antidote is known. Officially described procedures may include continuous monitoring of vital signs (temperature, pulse, blood pressure), maintenance of respiration, and administration of activated charcoal or other measures to assist drug elimination.

Therapeutic Uses of Narkodorm

What Narkodorm Treats: Main Uses and Benefits

The therapeutic role of Narkodorm (Pentobarbital) is generally focused on its supportive effect in managing acute and critical care contexts where short-term symptomatic assistance is needed.

Its therapeutic relevance is generally focused on managing three key areas: severe seizure activity, supporting deep sedation, and providing short-term hypnotic support.

This medication is commonly used to help manage symptoms related to severe, generalized seizure activity, particularly in conditions characterized by periods of heightened symptoms like continuous, refractory convulsions. It is also relevant for easing symptoms related to heightened physiological activity, such as profound agitation or anxiety, which interfere with daily functioning for required medical procedures. In critical care settings, it may be part of symptomatic management for severe conditions, including refractory intracranial hypertension.

“It is used in acute contexts where rapid, supportive symptom management is appropriate during severe neurological or agitation episodes.”

This application provides support that helps ease symptoms of physical discomfort by supporting deep short-term hypnosis and assists with maintaining functional stability for necessary procedures. It also provides support that helps ease the overall symptom burden associated with excessive neurological stress.

Key Supportive Contexts: Areas of Symptom Focus

Area of Use Symptomatic Benefit
Emergency Neurology Assists with easing symptoms of increased neurological activity.
Procedural Support Provides support that helps ease symptoms of physical discomfort for required medical interventions.
Critical Care Supports the patient by easing the overall symptom burden associated with brain stress.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

The eligibility to use Narkodorm (Pentobarbital) is strictly defined by government regulatory documents, focusing on patient health status, age, and reproductive condition.

Eligibility Scope

Classification Population Rule (Based on Official Labeling)
Absolute Contraindications Prohibited for patients with hypersensitivity to barbiturates or a history of manifest or latent porphyria.
Organ Function Restriction Use is restricted in patients with severe hepatic impairment or signs of impending hepatic coma, and caution is required with renal impairment.
Age-Related Rules Use in older adults requires a reduced initial dose due to increased sensitivity. Repeated or prolonged use in children under 3 years of age is cautioned against due to potential negative effects on brain development.
Pregnancy/Lactation Status Use during pregnancy is restricted (FDA Category D); the patient must be informed of the potential hazard to the fetus. Use during breastfeeding is also cautioned against, as the drug is excreted into breast milk.
Other Restrictions Contraindicated in individuals with severe respiratory depression and generally not recommended for patients with uncontrolled pain or a history of drug abuse.

Connection to the Overall Eligibility Profile

Regulatory documents establish the population boundaries for Narkodorm by setting clear absolute exclusions based on metabolic and allergic risks. This official profile mandates cautious or limited use in vulnerable groups—specifically the elderly, individuals with compromised organ function, and pregnant or lactating women—to manage risks that are explicitly documented in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Narkodorm (Pentobarbital) focuses on two major types of documented interactions: those related to enzyme induction and those resulting in additive effects on the central nervous system (CNS).

Interaction Type Affected Substances / Restrictions
Enzyme Induction Pentobarbital is a strong inducer of hepatic microsomal enzymes (e.g., CYP3A4, CYP2C families), which increases the metabolism and clearance of numerous other drugs. This leads to decreased plasma concentrations and potential loss of effectiveness for medicines such as Oral Anticoagulants, Oral Contraceptives, Corticosteroids, and Doxycycline [Source FDA].
Pharmacodynamic Co-administration with other CNS Depressants (including Opioids, Benzodiazepines, Antihistamines, and Alcohol) may produce additive CNS depressant effects, which carries a risk of profound respiratory depression and cardiovascular events.

Officially Contraindicated Combinations

The most severe interaction restrictions are related to the enzyme-induction property. Co-administration is formally contraindicated with specific strong CYP3A4 substrates (e.g., Lorlatinib, Cariprazine, Cobimetinib), as this may result in treatment failure of the substrate drug [Source Medscape/Regulatory]. Acute alcohol intoxication resulting in depressed vital signs is also a contraindication [Source NIH].

Exposure and Timing Constraints

Substances like Valproic Acid are documented to potentially increase Pentobarbital exposure, necessitating caution. Due to enzyme induction, official regulatory documents require mandatory timing separation for co-administered drugs: strong CYP3A inducers must be discontinued for a specified duration (e.g., 3 plasma half-lives before initiating Lorlatinib) [Source Medscape/Regulatory]. Furthermore, caution is advised for patients with hepatic impairment due to the drug’s metabolic reliance [Source FDA].

Mechanism of Action

Narkodorm acts primarily by engaging specific inhibitory receptor proteins within the central nervous system (CNS). This interaction enhances the natural function of these receptors, which are involved in dampening neuronal activity.


Modulating Central Inhibitory Pathways

The drug binds directly to its biological targets, which are integral to inhibitory signaling pathways, causing a direct potentiation of the receptor's activity. This action initiates a mechanistic cascade that modulates the rate of excitatory transmission.


Targeted Regulation of Signaling Dynamics

Narkodorm's enhancement of inhibitory signals alters the signal transduction cascades within defined neural networks. By amplifying this dampening effect, the drug influences the activity of defined physiological response pathways, which results in an alteration of pathway activity states.


Defining Resulting Physiological Activity

The sustained modulation of signaling dynamics alters the physiological activity pattern and modulates the intensity of neuronal signaling, thereby defining the resulting physiological activity.

Dosage and Administration Information

The official administration of Narkodorm (Pentobarbital sodium) is governed by specific instructions concerning route, dosage, and rate. The primary methods of use are Intravenous (IV) and Intramuscular (IM) injection; the IV route is typically reserved for acute, controlled settings.

Official Administration Guidelines

Instruction Detail
Route of Administration Intravenous (IV) and Intramuscular (IM) injection.
Adult Dosing (Example) For IM hypnotic use, a single dose is typically 150 mg to 200 mg. IV administration is incremental, often beginning with 100 mg, with a maximum total dose ranging from 200 mg to 500 mg.
Administration Rate The intravenous injection rate must not exceed 50 mg per minute.
Duration Constraint Use as a hypnotic agent should generally not exceed two weeks of continuous administration.

The standardized use protocol requires precise management of the injection speed and the interval between doses. When administered intravenously, the drug must be injected slowly, and a period of at least one minute should elapse between subsequent small increments to assess the effect fully. For IM use, the maximum volume administered at a single site is typically limited to 5 mL.

Dosing principles also require modification for certain groups: pediatric doses are determined on a weight-based basis (e.g., mg/kg), and a reduced dosage is recommended for older adults and individuals with hepatic or renal impairment. Following prolonged use, the medicine must be withdrawn gradually, not abruptly, which is a required procedure for discontinuation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Narkodorm

Narkodorm contains the active ingredient Pentobarbital, which was evaluated in specific, acute clinical settings. Research has explored the medicine’s use in three main contexts: in the context of severe seizure activity, monitoring high pressure inside the skull, and providing deep sedation for procedures. The available evidence comes primarily from systematic reviews, which summarize existing data, and observational studies, rather than large-scale randomized controlled trials (RCTs).


Evidence for Use in Managing Severe Seizures (Refractory Status Epilepticus)

This evidence was evaluated in studies focusing on conditions involving periods of heightened symptoms, specifically a type of seizure activity called Refractory Status Epilepticus (RSE). Research explored the purpose of seizure termination and monitored outcomes related to physiological strain or stress. Studies generally report measurements related to seizure termination in patients receiving the agent. However, prospective, randomized controlled trials designed to compare this agent directly against modern infusion therapies are not fully established. Because data largely rely on retrospective cohort analyses, evidence is limited regarding the medicine's unique influence on long-term functional recovery or survival rates. The long-term functional recovery and mortality outcomes reported were mixed across the different retrospective cohorts that were reviewed.


Evidence in Critical Care for Controlling Intracranial Pressure

The medicine was observed in research exploring its use in critical care for monitoring Refractory Intracranial Hypertension (RICH). This research examined outcomes related to systemic or functional imbalance, with the primary physiological outcome measured as the monitoring and recording of Intracranial Pressure (ICP) levels. Research generally reports that the agent was associated with changes in elevated ICP levels in the patients observed. The overall body of evidence related to its use for major outcomes is of low quality. While the studies monitored the immediate physiological response, the evidence is limited to consistently associate the use of this agent with improved functional recovery or decreased mortality in adult patient groups.


Research Gaps and Uncertainties

The evidence base shows patterns related to several key limitations. The lack of randomized controlled trials directly comparing the agent to modern standard-of-care agents means that the comparative evidence is lacking. Furthermore, the studies help show what has been observed so far, but there is limited information for long-term outcomes, meaning the certainty remains low when discussing final outcomes and long-term functional status across all indications.

Key Studies & References Management of Refractory Intracranial Hypertension: An Evidenced-Based Review

Frequently Asked Questions (FAQ)

Common questions about Narkodorm (FAQ)


Q: Is Narkodorm a controlled substance?

The active ingredient, pentobarbital, is categorized as a federally controlled substance. In the United States, official documents classify it as a Schedule II drug, which indicates a high potential for abuse. Due to this classification, the medicine is subject to strict controls regarding prescription and dispensing, and its storage often involves secure measures.


Q: Does Narkodorm make you feel sleepy the day after taking it?

Official regulatory information notes that a common adverse reaction is somnolence, which means excessive sleepiness. A 'hangover' effect characterized by residual drowsiness or mental slowing the day after a dose is also documented as a potential effect of the drug.


Q: How long does the effect of Narkodorm last once it is working?

The active ingredient in this medicine, pentobarbital, is classified pharmacologically as a short-acting barbiturate. This classification indicates that the drug's therapeutic effects are designed to have a rapid onset and a relatively brief duration of action.


Q: What is the risk of having a serious side effect from Narkodorm?

Regulatory documents detail potentially serious adverse reactions, which include severe respiratory depression, cardiovascular collapse, and serious dermatologic reactions such as Stevens-Johnson syndrome. The potential risk of these serious events is noted, particularly with rapid administration.


Q: Can Narkodorm be taken at the same time as cold or allergy medicine?

Official regulatory documents contain warnings regarding co-administration with other CNS depressants (medicines that slow brain activity). Many common cold and allergy medicines contain ingredients like antihistamines, which are CNS depressants and could cause additive effects, potentially increasing sedation or respiratory risk.


Q: Does Narkodorm affect my ability to drive the next morning?

Yes. Official labeling contains a mandatory warning that barbiturates may impair mental and physical abilities required for performing potentially hazardous tasks. These tasks specifically include driving or operating complex machinery.


Q: Does Narkodorm interact with common supplements like melatonin or magnesium?

Official interaction information focuses on medicines classified as CNS depressants or enzyme inducers. Since the drug is a CNS depressant, any product, including a supplement, that promotes sedation or relaxation could contribute to additive depressant effects.


Q: Is Narkodorm approved for use in children or teenagers?

The medicine is used in pediatric patients, with the dose determined based on weight. However, regulatory documents caution specifically against the repeated or prolonged use in children younger than 3 years due to potential negative effects on brain development.


Q: Why is Narkodorm sometimes prescribed for conditions other than its main use?

Regulatory documents list the medicine's use for several critical settings beyond its use for sedation and hypnosis. These uses include the context of managing severe seizure activity (refractory status epilepticus), controlling intracranial pressure, and providing deep sedation for procedures.


Q: What is the significance of the research evidence for Narkodorm?

The evidence base primarily reports on the medicine's association with physiological effects, such as seizure termination and changes in elevated intracranial pressure. Regulatory documents note that the quality of the evidence is often low and that information is limited for long-term functional recovery outcomes.


Q: Can Narkodorm change my mood or cause emotional changes?

Official documents report psychiatric and nervous system adverse reactions. These documented effects include agitation, confusion, nervousness, anxiety, and general psychiatric disturbance.


Q: Are there differences in how Narkodorm works compared to over-the-counter aids?

Yes. Narkodorm's mechanism is defined by its function as a barbiturate that significantly enhances the effects of the inhibitory neurotransmitter GABA. This powerful, nonselective pharmacological action is characteristic of the barbiturate class of medicines.


Q: Can I use Narkodorm if I have a history of heart issues?

Regulatory documents caution that the medicine can cause hypotension (low blood pressure) and bradycardia (slow heart rate). Use is formally contraindicated in patients with conditions that feature severe respiratory depression, which is a condition that can seriously affect cardiovascular stability.


Q: Is there a risk of rebound effects if Narkodorm is stopped suddenly?

Official documentation indicates a required procedure is that the drug be withdrawn gradually following prolonged use. Abrupt cessation after extended administration may precipitate severe withdrawal symptoms, which can include a return or worsening of original symptoms.


Q: Is it normal to have vivid dreams when taking Narkodorm?

Official documentation for the active ingredient lists nightmares under nervous system adverse reactions. These are noted as a potential effect that can occur while using this medicine.


Q: What should I do if a side effect of Narkodorm seems unusual?

Official regulatory information includes a procedure for reporting suspected adverse reactions. This typically involves contacting the manufacturer or the relevant governmental health authority, such as the FDA (Food and Drug Administration) in the United States.


Q: Is it true that Narkodorm can cause forgetfulness or memory issues?

Yes. Official documentation lists problems with memory or concentration as a potential adverse reaction. These effects are classified under nervous system disturbances.


Q: Does Narkodorm contain any common allergens like gluten or lactose?

The active ingredient is typically supplied as an injectable solution in a vehicle commonly composed of propylene glycol, alcohol, and water. While specific common food allergens like gluten or lactose are usually not listed, the full excipient composition is available in the official regulatory labeling.


Q: Can taking Narkodorm affect the results of a drug screening test?

Yes. As a barbiturate, the active ingredient pentobarbital is an analyte that is specifically screened for in standard urine or serum drug tests. A positive result may occur following the administration of this medicine.


Q: Can Narkodorm interact with medicines for high blood pressure?

Official labeling documents that the medicine itself can cause hypotension (low blood pressure). The potential for additive effects on blood pressure regulation exists when Narkodorm is used alongside other medicines that affect blood pressure.

How should Narkodorm be stored and disposed of?

Storage and Handling

Official regulatory labeling for Narkodorm (Pentobarbital sodium) defines strict storage and handling requirements. The medicine must be kept at Controlled Room Temperature, typically below 25,^circmathrmC or 30,^circmathrmC. It is mandatory to Protect from light and to Do not freeze the solution to preserve its stability.

To ensure safety, the product must be strictly stored out of the sight and reach of children and often requires storage in a locked up area due to its classification as a controlled substance. The container must be kept tightly closed and in its original package.

Disposal Instructions

Disposal of any unused or expired Narkodorm must be done in accordance with local regulatory requirements for controlled substances. Official instructions mandate that the medicine Do NOT be disposed of in household trash or poured down the drain. Instead, unused portions must be taken to an authorized drug take-back facility to comply with environmental protection and pharmaceutical waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Narkodorm found in:

A-Z Index: